Abstract:Key PointsThe recent failure of novel anti-atherosclerotic therapies in Phase III clinical trials has emphasized the pressing need for robust imaging markers that can reliably assist in the development of drugs for the treatment of atherosclerosis.Conventional methods of imaging atherosclerosis are able to provide quantitative and morphological data, and to date, have principally been used to assess the efficacy of cholesterol-lowering agents.In this article we compare the main imaging modalities used to image atherosclerosis in the clinical trial setting so far, namely quantitative coronary angiography (QCA), carotid intima-media thickness (CIMT), magnetic resonance imaging (MRI), computed tomography (CT) and intravascular ultrasound (IVUS). The ability of these imaging modalities to predict clinical outcomes for a given sample size, and the regulatory considerations pertaining to their use, are also discussed.However, these methods are likely to be inadequate to assess an emerging generation of therapies that modify plaque biology directly. For example, squalene synthase inhibitors, p38 mitogen-activated protein kinase (MAPK) inhibitors, and chemokine (C-C motif) receptor 2 (CCR2) antagonists.We outline how emerging molecular and cellular imaging techniques offer the possibility to quantify changes in biological function at the level of the plaque, even without gross structural change. In this regard, two imaging modalities are discussed in detail: MRI and positron-emission tomography (PET).Currently, no single ideal imaging modality exists. In the future, the careful application of imaging biomarkers will be necessary to ensure that new anti-atherosclerosis therapies are evaluated in the most efficient manner possible.

Imaging of atherosclerotic cardiovascular disease

Novel imaging modalities for the identification of vulnerable plaques

The vascular biology of atherosclerosis and imaging targets

Intravascular molecular imaging: translating pathophysiology of atherosclerosis into human disease conditions

Ultrasound Imaging for Risk Assessment in Atherosclerosis

Targeted Imaging in Atherosclerosis.

New Progress in Early Diagnosis of Atherosclerosis

Serial Magnetic-Resonance-Imaging of Experimental Atherosclerosis Detects Lesion Fine-Structure, Progression and Complications In-Vivo

Atherosclerosis imaging on the molecular level

Noninvasive Molecular Imaging of Disease Activity in Atherosclerosis

Detection and Imaging of Active Substances in Early Atherosclerotic Lesions using Fluorescent Probes

Molecular and Nonmolecular Imaging of Macrophages in Atherosclerosis

Molecular imaging of atherosclerosis with integrated PET imaging

Multimodal intravascular imaging technology for characterization of atherosclerosis

Current Advances in the Diagnostic Imaging of Atherosclerosis: Insights into the Pathophysiology of Vulnerable Plaque

Uncovering atherosclerotic cardiovascular disease by PET imaging

Current Development of Molecular Coronary Plaque Imaging using Magnetic Resonance Imaging towards Clinical Application

Form to function: current and future roles for atherosclerosis imaging in drug development

Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: What Leonardo da Vinci could not see

Intravascular photoacoustic detection of vulnerable plaque based on constituent selected imaging

Positron Emission Tomography Imaging of Atherosclerosis.